Full-Time
Senior Transformation Analyst
Syneos Health
10,001+ employees
Global provider of integrated clinical-to-commercial services
No salary listed
Hyderabad, Telangana, India
Hybrid
Hybrid role with on-site days in assigned location.
 Data & Analytics (1) |
|---|
Get referred to Syneos Health
See people who can refer or advise you
- Build and maintain dashboards and reports to track key performance indicators related to enterprise transformation efforts.
- Maintain predictive models from disparate datasets to support strategic decisions such as revenue burn analysis, employee turnover, and headcount forecasting.
- Support the design of executive-level reporting packs, surfacing relevant trends and data insights.
- Analyze workforce, cost, and operational data to uncover drivers of performance and areas of opportunity.
- Partner with Finance and People teams to ensure consistent use of data and alignment on core business metrics.
- Support business case development through financial modeling, ROI calculations, and comparative analysis of options and outcomes to inform strategic decision-making.
- Assist in maintaining standardized data models and definitions across multiple data sources and teams.
- Contribute to scenario modeling and ad-hoc analysis to inform strategic decisions.
- Ensure data integrity and consistency across reporting outputs.
- Communicate findings in a clear and compelling way, both visually and verbally.
- Expert utilization of PowerPoint and Excel. Comfortable presenting data outcomes and trends to executive leaders.
- Build and maintain dashboards and reports to track key performance indicators (KPIs) related to enterprise transformation efforts.
- Maintain predictive models from disparate datasets to support strategic decisions such as revenue burn analysis, employee turnover, and headcount forecasting.
- Support the design of executive-level reporting packs, surfacing relevant trends and data insights.
- Analyze workforce, cost, and operational data to uncover drivers of performance and areas of opportunity.
- Partner with Finance and People teams to ensure consistent use of data and alignment on core business metrics.
- Support business case development through financial modeling, ROI calculations, and comparative analysis of options and outcomes to inform strategic decision-making.
- Assist in maintaining standardized data models and definitions across multiple data sources and teams.
- Contribute to scenario modeling and ad-hoc analysis to inform strategic decisions.
- Ensure data integrity and consistency across reporting outputs.
- Communicate findings in a clear and compelling way, both visually and verbally.
- Expert utilization of Powerpoint and Excel. Comfortable presenting data outcomes and trends to executive leaders.
Syneos Health provides end-to-end biopharmaceutical solutions across the clinical-to-commercial spectrum. It helps biopharma companies, healthcare organizations, and investors by offering specialized expertise, insights, and technology-enabled services to move therapies faster to patients. Its offerings include Kinetic, a modern omnichannel customer engagement platform that uses targeting and analytics to coordinate nationwide healthcare communications, and Syneos One, an asset development approach that aligns strategy and execution from early concept through commercialization. The company uses AI and advanced tech to improve performance and reduce risk in drug development and market delivery. Its goal is to be a trusted partner that accelerates therapy development and delivery by combining scientific know-how with integrated, data-driven services.
Company Size
10,001+
Company Stage
IPO
Headquarters
Morrisville, North Carolina
Founded
1985
Get referred to Syneos Health
See people who can refer or advise you
Simplify's Take
What believers are saying
- Causaly cut study-strategy insight time about 50% by August 18, 2026.
- Databricks reduced clinical insight turnaround from days to hours, speeding interventions.
- Microsoft-powered 280 agents lifted internal productivity and workflow automation in 2026.
What critics are saying
- Italy announced 49 layoffs on March 25, 2026, signaling ongoing cost pressure.
- AI tools commoditize CRO analytics if sponsors replicate Syneos workflows in-house by 2027.
- Elliott, Patient Square, and Veritas can force harsher cuts, weakening delivery quality.
What makes Syneos Health unique
- Syneos bundles clinical development and commercialization across one operating platform.
- Its August 18, 2026 AI stack embeds Causaly, Databricks, and Microsoft into workflows.
- Private ownership since 2023 lets Syneos retool faster than public CRO peers.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Employee Stock Purchase Plan
Flexible Work Hours
Paid Vacation
Paid Sick Leave
Remote Work Options
Company News
Syneos Health expands AI ecosystem with three new platform partnerships. New collaborations with Causaly, Databricks, and Microsoft anchor a broader push to embed artificial intelligence directly into clinical trial decision-making and operational workflows. "When technology is applied precisely at critical decision points, teams can anticipate risk earlier to accelerate development." Syneos Health has announced the continued expansion of its artificial intelligence (AI) ecosystem, detailing three platform partnerships designed to embed AI into core clinical development workflows.[1] The three partnerships each target a distinct layer of the clinical development stack. Through a new collaboration with Causaly, Syneos is applying agentic, evidence-based scientific reasoning to accelerate protocol strategy development, feasibility planning, and competitive trial intelligence. Causaly's platform surfaces evidence from a proprietary knowledge graph combining biomedical research and commercial insights. According to the company, the integration has reduced the time it takes to derive insights for study strategy and design by approximately 50%. The partnership with Databricks focuses on the data infrastructure layer. By leveraging the Databricks Data and AI Platform, Syneos has developed a near real-time view of clinical operations that reduces the time from source data capture to review-ready insight from days to hours, enabling faster intervention and more efficient trial execution. The Microsoft collaboration, which builds on a relationship that began in 2023, extends AI adoption through productivity and workflow tools. Syneos has used Microsoft Power Apps and other tools to develop more than 280 agents that integrate with Microsoft 365 Copilot to streamline workflows and support faster decision-making across the organization. "When technology is applied precisely at critical decision points, teams can anticipate risk earlier to accelerate development," said Mike Montello, chief digital and information officer at Syneos Health, in a company press release. Together, the three partnerships are designed to create what Syneos Health describes as a unified intelligence environment - connecting operational, clinical, and real-world data across the development lifecycle. The company noted that all capabilities are deployed with human oversight and governance to ensure responsible use in regulated environments. A broader conversation about AI and site readiness. The Syneos announcement reflects a pattern Applied Clinical Trials has been tracking closely: sponsor investment in AI is accelerating, but questions about how that technology reaches sites - and whether it actually fits their workflows - remain unresolved. In a recent with ACT, Liz Beatty, co-founder and chief strategy officer at Inato, addressed that tension directly.[2] Beatty argued that the industry has consistently made the mistake of building technology for sponsors rather than for sites. "We need to stop, and instead think: how can I enable sites to use this technology to become more efficient and effective in clinical trials, which then helps my trial and my company - not the other way around," she said. On where AI is delivering measurable enrollment impact, Beatty pointed to real-time patient data as the most significant shift. Rather than relying on feasibility questionnaires and sponsor-discounted estimates, AI tools can now identify which specific patients at a given site currently meet study criteria. In a chronic obstructive pulmonary disease case study, than those that did not, and 100% of sites using the tool were able to successfully screen and enroll patients. Looking ahead, Beatty pointed to a structural shift she sees gaining momentum: sponsors moving away from trial-by-trial site planning toward program or cross-asset planning, building deeper site partnerships across multiple studies. This represents a dynamic that could meaningfully change how enrollment bottlenecks are addressed before a trial even begins. References
Syneos Health advances ai-powered clinical ecosystem to optimize trial performance and speed decision-making. Expanding set of partners and proprietary insights strengthens operational performance. MORRISVILLE, N.C., Aug. 18, 2026 (GLOBE NEWSWIRE) - Syneos Health(R), a leading fully integrated biopharmaceutical solutions organization, today announced the continued advancement of its AI ecosystem - a unified, enterprise approach that embeds artificial intelligence (AI) directly into the core of clinical development. By combining deep therapeutic expertise, healthcare professional intelligence and modern AI technologies, Syneos Health is helping sponsors navigate an increasingly complex development landscape. Grounded in decades of clinical and commercial experience, Syneos Health's differentiated AI approach focuses on integrating advanced capabilities into critical decision points across protocol design, feasibility, enrollment planning, site activation, monitoring and operational oversight. This enables teams to anticipate risk earlier, reduce friction across workflows and make faster, more informed decisions that improve study performance. "Our priority is AI that works inside the complexity of clinical trials. By combining advanced AI with a deep understanding of sites, physicians, patients and the operational dynamics that shape trial performance, we're unlocking new opportunities for speed, clarity and quality," said Mike Montello, Chief Digital and Information Officer, Syneos Health. "When technology is applied precisely at critical decision points, teams can anticipate risk earlier to accelerate development." Enterprise AI and Data Platforms Syneos Health is building a future ready ecosystem bringing together capabilities combining scientific expertise, connected data and evidence, and AI-enabled execution. This integrated approach creates a unified intelligence environment that enables faster, more informed decisions across the clinical development lifecycle. * Causaly - Syneos Health's new collaboration with Causaly applies agentic, evidence-based scientific reasoning to enable faster protocol strategy development, feasibility planning and competitive trial intelligence. Built specifically for the life sciences sector, Causaly's Agentic Research surfaces evidence from a proprietary knowledge graph combining biomedical research and commercial insights. By accelerating analysis of complex biomedical literature and emerging data, Syneos Health teams have reduced the time it takes to derive insights for study strategy and design by approximately 50%. * Databricks - Using Databricks enables Syneos Health to create a more powerful, unified intelligence environment that brings together operational, clinical and real-world data to advance modern clinical development. Leveraging the Databricks Data + AI Platform, Syneos Health has developed a continuous, near real-time view of clinical operations that reduces the time from source data capture to review-ready insight from days to hours, enabling faster intervention and more efficient trial execution. * Microsoft - Building on its long-standing collaboration that began in 2023, Syneos Health is driving AI adoption through its integration with Microsoft. Specifically, Syneos Health has used Microsoft Power Apps and other tools to develop more than 280 agents that integrate with Microsoft 365 Copilot to improve productivity, streamline workflows and support faster, more confident decision-making across the company. Complementing these foundational capabilities are frontier agentic AI solutions and proprietary Syneos Health insights embedded directly within clinical workflows. Together, they help improve predictability, reduce operational complexity, and drive more precise, scalable trial performance. These capabilities are deployed with strong human oversight and governance, ensuring responsible use in regulated environments. "What differentiates Syneos Health is our ability to redesign how clinical development decisions are made through the combination of scientific intelligence, connected evidence, operational expertise and AI-enabled execution across the development lifecycle," said Michael Brooks, Chief Operating Officer, Syneos Health. "By grounding AI in deep clinical expertise and real-world experience, we help sponsors reduce complexity, make better-informed decisions and ultimately deliver better outcomes for patients." About Syneos Health Syneos Health(R) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. News Break Middle East translate unique clinical, commercial and real world insights into outcomes to address modern market realities. News Break Middle East bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together News Break Middle East share diverse insights, use the latest technologies and apply advanced business practices to speed its customers' delivery of important therapies to patients. Syneos Health is powered by an authentic, inclusive and high-performance culture that cares for colleagues, customers, patients, communities and the environment. Press/Media Contact: Meg Byers Director, External Communications [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. News Break Middle East do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Inovio Pharmaceuticals (NASDAQ:INO) releases quarterly earnings results, beats expectations by $0.15 EPS. August 12, 2026 Key points. * Inovio beat earnings expectations: The company reported a quarterly loss of $0.07 per share, $0.15 better than the consensus estimate of a $0.22 loss. * INO-3107 remains on track for FDA review: The treatment's October 30, 2026 PDUFA date is intact, and Inovio is advancing launch preparations, though accelerated approval and final timing remain uncertain. * Funding remains a concern: Inovio ended the quarter with $36.7 million in cash and expects about $18 million in operational cash burn during the third quarter; a July equity offering is expected to fund operations into late Q1 2027, excluding additional capital raises. * Five stocks we like better than Inovio Pharmaceuticals. Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.15, FiscalAI reports. Here are the key takeaways from Inovio Pharmaceuticals' conference call: * Positive Sentiment: INO-3107's FDA review remains on track for the October 30, 2026 PDUFA date; late-cycle review and pre-licensure inspections are complete, with only one reported inspection observation that the company believes it has addressed. * Positive Sentiment: Inovio is advancing launch preparations for INO-3107, including label negotiations expected to begin in September, medical science liaison activities, and a commercialization agreement with Syneos Health. If approved, the company expects seven years of orphan-drug market exclusivity. * Negative Sentiment: The FDA has not yet indicated whether INO-3107 qualifies for accelerated approval, and feedback on the confirmatory-trial design remains outstanding. The company continues to characterize approval and launch timing as potential outcomes rather than assured results. * Negative Sentiment: Inovio ended the quarter with $36.7 million in cash, cash equivalents, and short-term investments, and expects approximately $18 million of operational net cash burn in Q3. July's $18.3 million equity offering extends funding into late Q1 2027 and through a potential launch, but the company noted that this projection excludes future capital raises. * Positive Sentiment: Partner ApolloBio reported positive pivotal Phase III results for VGX-3100 in cervical dysplasia, meeting its primary efficacy endpoint and supporting plans for a potential regulatory filing in China. Inovio also reported encouraging preclinical progress for its DPROT platform in hemophilia A and other rare diseases. Inovio Pharmaceuticals price performance. Inovio Pharmaceuticals stock traded up $0.00 during mid-day trading on Wednesday, hitting $0.77. 3,060,340 shares of the company were exchanged, compared to its average volume of 2,293,542. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.98. The company has a market capitalization of $63.35 million, a P/E ratio of -0.53 and a beta of 1.52. The business's 50 day simple moving average is $1.04 and its two-hundred day simple moving average is $1.31. Wall Street analyst weigh in. Several equities analysts recently issued reports on INO shares. Wall Street Zen cut Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Sunday, June 21st. HC Wainwright lowered their target price on Inovio Pharmaceuticals from $3.00 to $2.50 and set a "neutral" rating on the stock in a report on Monday, June 1st. Weiss Ratings upgraded Inovio Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 29th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $4.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $3.25. Discover more Track Market Trends Stock split calculator Earnings screener tool Institutional trading of Inovio Pharmaceuticals. A number of large investors have recently made changes to their positions in INO. Millennium Management LLC raised its position in shares of Inovio Pharmaceuticals by 468.7% in the third quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company's stock valued at $4,616,000 after buying an additional 1,625,653 shares during the last quarter. Vanguard Group Inc. boosted its position in Inovio Pharmaceuticals by 35.0% during the third quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company's stock worth $6,348,000 after acquiring an additional 703,727 shares during the last quarter. 683 Capital Management LLC acquired a new stake in Inovio Pharmaceuticals during the fourth quarter worth approximately $433,000. OMERS ADMINISTRATION Corp purchased a new stake in Inovio Pharmaceuticals in the 4th quarter worth approximately $388,000. Finally, Geode Capital Management LLC grew its stake in Inovio Pharmaceuticals by 40.7% in the 4th quarter. Geode Capital Management LLC now owns 769,356 shares of the biopharmaceutical company's stock worth $1,340,000 after acquiring an additional 222,609 shares during the period. Institutional investors and hedge funds own 26.79% of the company's stock. About Inovio Pharmaceuticals. Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats. Central to Inovio's platform is its SynCon(R) technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra(R) electroporation device, designed to enhance cellular uptake and expression of DNA vaccines. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Inovio Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list. While Inovio Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Helio Genomics has partnered with Syneos Health to accelerate nationwide adoption of HelioLiver, an AI-powered blood test for early liver cancer detection. Syneos Health will deploy field engagement and educational initiatives to reach hepatologists and gastroenterologists managing high-risk populations across the United States. HelioLiver combines cell-free DNA methylation patterns, protein biomarkers and patient demographics using proprietary AI algorithms. In the CLiMB trial involving nearly 1,968 patients across 50 clinical sites, the test demonstrated four times greater sensitivity for Stage I liver cancer compared to ultrasound. The test is reimbursed by Medicare at $662. The partnership builds on Helio Genomics' recent collaboration with Quest Diagnostics, providing access to over 7,700 patient service centres nationwide. Liver cancer incidence rates have tripled in the US since 1980.
KAI Conversations announces strategic partnership with Syneos Health to advance U.S. Pharmaceutical commercialization. GlobeNewswire | Syneos Health, Inc. Today at 9:30am PDT LONDON, April 30, 2026 (GLOBE NEWSWIRE) - KAI Conversations, an AI-powered conversation intelligence platform purpose-built for the pharmaceutical industry, today announced a strategic partnership with Syneos Health(R), a leading fully integrated biopharmaceutical solutions organization, to bring AI-driven field insights to the U.S. biopharma market. Pharmaceutical companies invest an estimated 30-50% of revenue in field teams, yet the majority of HCP interactions fail to translate into meaningful impact. This collaboration is designed to address that gap by helping companies turn everyday field conversations into actionable insights, more effective engagement and stronger brand performance. Through this strategic partnership, Syneos Health will embed KAI's platform into its commercial solutions - among the broadest in the industry - further strengthening the Company's ability to optimize field execution, accelerate behavior change and translate data-driven signals into measurable performance gains. KAI's platform, used by 10 of the top 20 global pharmaceutical companies across 15 therapeutic areas and multiple continents, analyzes conversations between field teams and healthcare professionals (HCPs). The platform delivers coaching to individual sales representatives while generating aggregated brand and customer intelligence for commercial and medical leaders. "The U.S. market represents a critical opportunity for pharmaceutical innovation and commercialization," said David Williams, Founder and CEO of KAI Conversations. "Partnering with Syneos Health enables us to scale our conversation intelligence through a trusted commercialization leader - equipping field teams with contextual coaching and insights to drive HCP engagement and stronger brand outcomes." "For years, valuable field insights were effectively invisible, locked inside everyday HCP conversations," said Paul Mignon, Head of Deployment Solutions at Syneos Health. "With KAI, we're surfacing real-time signals so our expert teams can optimize what works, predict what matters and automate next-best actions - driving precision performance to accelerate launch, adoption and growth." Together KAI and Syneos Health are advancing pharmaceutical commercialization by aligning AI-powered insights with integrated strategy, commercial execution and performance optimization. About KAI Conversations KAI Conversations is the world's leading AI conversation intelligence platform purpose-built for the pharmaceutical industry. The platform reveals previously hidden human insights by analyzing conversations between pharmaceutical field teams and healthcare professionals. By providing actionable insights and coaching, KAI empowers individuals and central teams to drive more effective engagement, enhance commercial outcomes, and accelerate brand performance. For more information, visit kaiconversations.com. This is a paid placement. For further inquiries, please contact GlobeNewswire directly.